Mablink Bioscience, the next generation ADC company, raises €4M from a syndicate of private investors. Jérémie Waicenberg, Senior Business Analyst at...
The financing round led by Fidelity and T. Rowe Price funds underscores vast opportunities to bring Inscripta’s CRISPR-based technology to the broader...
Jérôme Bédier joins as Chief Operating Officer and Guillaume Lay as Global Business Development Manager.
The Fund will be dedicated to Growth & Buyout, with a target of €500M. (article in Les Echos)
This acquisition transforms the group into a global leader and a fully integrated specialty pharmaceutical platform.
The company will use the proceeds of the Series A financing to conduct clinical trials for its robotic ocular microsurgery platform and reach...
Plantex is a French manufacturer of high quality natural plant extracts for nutraceutical, dietary, animal nutritional and cosmetic purposes.
This operation would enable Elsan and C2S to become the number one private healthcare operator in France.
CTRS is a French pharmaceutical company that develops and markets treatments for patients with strong unmet medical needs, with a particular focus on...
Cell-Easy is a stem cell Contract Development and Manufacturing Organization (CDMO) that provides ready-to-inject adipose-derived allogeneic stem...
